- Home
- MDGL vs BYD Comparison
MDGL vs BYD Comparison
Compare MDGL & BYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- BYD
- Stock Information
- Founded
- MDGL 2011
- BYD 1973
- Country
- MDGL United States
- BYD United States
- Employees
- MDGL N/A
- BYD N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- BYD Hotels/Resorts
- Sector
- MDGL Health Care
- BYD Consumer Discretionary
- Exchange
- MDGL Nasdaq
- BYD Nasdaq
- Market Cap
- MDGL 7.1B
- BYD 6.9B
- IPO Year
- MDGL N/A
- BYD 1993
- Fundamental
- Price
- MDGL $336.23
- BYD $76.85
- Analyst Decision
- MDGL Buy
- BYD Buy
- Analyst Count
- MDGL 14
- BYD 16
- Target Price
- MDGL $351.67
- BYD $95.07
- AVG Volume (30 Days)
- MDGL 357.1K
- BYD 987.8K
- Earning Date
- MDGL 02-26-2025
- BYD 02-06-2025
- Dividend Yield
- MDGL N/A
- BYD 0.94%
- EPS Growth
- MDGL N/A
- BYD 1.16
- EPS
- MDGL N/A
- BYD 6.19
- Revenue
- MDGL $76,813,000.00
- BYD $3,930,194,000.00
- Revenue This Year
- MDGL N/A
- BYD $0.89
- Revenue Next Year
- MDGL $195.95
- BYD $2.17
- P/E Ratio
- MDGL N/A
- BYD $12.42
- Revenue Growth
- MDGL N/A
- BYD 5.13
- 52 Week Low
- MDGL $189.00
- BYD $49.34
- 52 Week High
- MDGL $368.29
- BYD $80.50
- Technical
- Relative Strength Index (RSI)
- MDGL 52.41
- BYD 50.30
- Support Level
- MDGL $334.13
- BYD $78.25
- Resistance Level
- MDGL $354.49
- BYD $80.02
- Average True Range (ATR)
- MDGL 13.20
- BYD 1.81
- MACD
- MDGL 0.16
- BYD -0.07
- Stochastic Oscillator
- MDGL 43.12
- BYD 34.82
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
About BYD Boyd Gaming Corporation
Boyd Gaming Corp is a multi-jurisdictional gaming company. The company operates wholly-owned gaming entertainment properties (casino space, slot machines, table games, and hotel rooms) in Nevada, Illinois, Indiana, Iowa, Kansas, Louisiana, Mississippi, Missouri, Ohio, and Pennsylvania. Geographical regions separate its business segments: Las Vegas Locals, Downtown Las Vegas, Midwest and South, and Online. Midwest and South hold the key number of entertainment properties, and it generate the majority of sales for the company.